We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Authorized Generics May Draw More FTC Scrutiny, Expert Says
Authorized Generics May Draw More FTC Scrutiny, Expert Says
October 4, 2005
The lure of authorized generics (AGs) has caused some generics makers to jump ship and forge partnerships with brand firms, but regardless of generic drugmaker support, AG deals may start to face more FTC scrutiny over their long-term anti-competitive effects, industry experts said at the recent Institute for International Research’s annual Generic Drugs Summit.